<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">24952935</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>23</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1879-114X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>36</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jun</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical therapeutics</Title>
                <ISOAbbreviation>Clin Ther</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>847-862.e1</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinthera.2014.05.010</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0149-2918(14)00267-7</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Exosomes are small (30- to 100-nm) vesicles secreted by all cell types in culture and found in most body fluids. A mean of 1 mL of blood serum, derived from healthy donors, contains approximately 10(12) exosomes. Depending on the disease, the number of exosomes can fluctuate. Concentration of exosomes in the bloodstream and all other body fluids is extremely high. Several B-cell surface antigens (CD19, CD20, CD22, CD23, CD24, CD37, CD40, and HLA-DR) and the common leukocyte antigen CD45 are interesting in terms of immunotherapy of hematologic malignant neoplasms. The established standard for exosome isolation is ultracentrifugation. However, this method cannot discriminate between exosome subpopulations and other nanovesicles. The main purpose of this study was to characterize CD81(+) and CD63(+) subpopulations of exosomes in terms of these surface markers after release from various types of B-cell lymphoma cell lines using an easy and reliable method of immunomagnetic separation.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Western blotting, flow cytometry, and electron microscopy were used to compare the total preenriched extracellular vesicle (EV) pool to each fraction of vesicles after specific isolation, using magnetic beads conjugated with antibodies raised against the exosome markers CD63 and CD81.</AbstractText>
                <AbstractText Label="FINDINGS" NlmCategory="RESULTS">Magnetic bead-based isolation is a convenient method to study and compare subpopulations of exosomes released from B-cell lymphoma cells. The data indicated that the specifically isolated vesicles differed from the total preenriched EV pool. CD19, CD20, CD24, CD37, and HLA-DR, but not CD22, CD23, CD40, and CD45, are expressed on exosomes from B-cell lymphoma cell lines with large heterogeneity among the different B-cell lymphoma cell lines. Interestingly, these B-cell lymphoma-derived EVs are able to rescue lymphoma cells from rituximab-induced complement-dependent cytotoxicity.</AbstractText>
                <AbstractText Label="IMPLICATIONS" NlmCategory="CONCLUSIONS">Distribution of exosomes that contain CD19, CD20, CD24, CD37, and HLA-DR may intercept immunotherapy directed against these antigens, which is important to be aware of for optimal treatment. The use of an immunomagnetic separation platform enables easy isolation and characterization of exosome subpopulations for further studies of the exosome biology to understand the potential for therapeutic and diagnostic use.</AbstractText>
                <CopyrightInformation>Copyright Â© 2014 The Authors. Published by EM Inc USA.. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Oksvold</LastName>
                    <ForeName>Morten P</ForeName>
                    <Initials>MP</Initials>
                    <Affiliation>Department of Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kullmann</LastName>
                    <ForeName>Anette</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Life Technologies AS, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Forfang</LastName>
                    <ForeName>Lise</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kierulf</LastName>
                    <ForeName>Bente</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Life Technologies AS, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Mu</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Life Technologies AS, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brech</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vlassov</LastName>
                    <ForeName>Alexander V</ForeName>
                    <Initials>AV</Initials>
                    <Affiliation>Life Technologies AS, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smeland</LastName>
                    <ForeName>Erlend B</ForeName>
                    <Initials>EB</Initials>
                    <Affiliation>Department of Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neurauter</LastName>
                    <ForeName>Axl</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Life Technologies AS, Oslo, Norway.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pedersen</LastName>
                    <ForeName>Ketil W</ForeName>
                    <Initials>KW</Initials>
                    <Affiliation>Life Technologies AS, Oslo, Norway. Electronic address: Ketil.pedersen@lifetech.com.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Ther</MedlineTA>
            <NlmUniqueID>7706726</NlmUniqueID>
            <ISSNLinking>0149-2918</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">B-cell lymphoma</Keyword>
            <Keyword MajorTopicYN="N">B-cell surface antigens</Keyword>
            <Keyword MajorTopicYN="N">exosomes</Keyword>
            <Keyword MajorTopicYN="N">flow cytometry</Keyword>
            <Keyword MajorTopicYN="N">immunotherapy</Keyword>
            <Keyword MajorTopicYN="N">magnetic beads</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0149-2918(14)00267-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.clinthera.2014.05.010</ArticleId>
            <ArticleId IdType="pubmed">24952935</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
